Author

M. Minden

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 4 Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

A. Arruda· 2 shared A. Mitchell· 2 shared A. Murison· 2 shared C. Arlidge· 2 shared H. Boutzen· 2 shared J. Dick· 2 shared M. Lupien· 2 shared N. Chapal-Ilani· 2 shared

Activity by Year

2021-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Arruda

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Acute myeloid leukemia mitochondria hydrolyze ATP to resist chemotherapy

J. T. Hagen, M. Montgomery, R. Aruleba, B. Chrest, T. D. Green, M. Kassai, T. Zeczycki, C. A. Schmidt, D. Bhowmick, S.-F. Tan, D. Feith, C. Chalfant, T. Loughran, D. Liles, M. Minden, , K. Fisher-Wellman

This study identifies a bioenergetic mechanism in AML cells where mitochondria consume ATP to resist chemotherapy, offering a target for improving treatment.

bioRxiv · Apr 12, 2024 · PreprintCancer Biology

A primary patient-derived model for investigating functional heterogeneity within the human Leukemic Stem Cell Compartment

H. Boutzen, M. Chan-Seng-Yue, A. Murison, N. Mbong, E. Wagenblast, C. Arlidge, S. A. Madani Tonekaboni, E. Orouji, A. Arruda, A. Mitchell, F. Notta, M. Lupien, M. Minden, K. Kaufmann, J. Dick

bioRxiv · Mar 1, 2022 · PreprintCancer Biology

Rock inhibitors target SRSF2 leukemia by disrupting cell mitosis and nuclear morphology

M. Su, T. Fleisher, I. Grosheva, M. B. Horev, M. Olszewska, B. Haim, A. Plotnikov, S. Carvalho, Y. Moskovitz, M. Minden, N. Chapal-Ilani, E. P. Papapetrou, N. Dezorella, T. Cheng, N. Kaushansky, , L. I. Shlush

This study identifies ROCK inhibitors as effective targeting agents for SRSF2 mutant leukemia by disrupting mitosis and nuclear morphology in vitro and in xenograft models.

bioRxiv · Feb 15, 2022 · PreprintCancer Biology

Inflammatory signals from fatty bone marrow supports the early stages of DNMT3a driven clonal hematopoiesis

N. Zioni, A. Bercovich, N. Chapal-Ilani, A. Solomon, E. Petrovich, M. .Sacma, H. Geiger, M. Scheller, C. Müller-Tidow, D. Lipka, E. Shlush, M. Minden, N. Kaushansky, L. Shlush

This study shows that fatty bone marrow (FBM) promotes DNMT3A-driven clonal hematopoiesis by enhancing inflammatory signals like IL-6, which can be inhibited by blocking the IL-6 receptor.

bioRxiv · Jan 13, 2022Cancer Biology

Transposable Elements Shape Stemness in Normal and Leukemic Hematopoiesis

G. Grillo, B. Nadorp, A. Qamra, A. Mitchell, C. Arlidge, A. Nand, N. Takayama, A. Murison, S. A. M. Tonekaboni, A. Arruda, J. Wang, M. Minden, O. Deniz, H. Boutzen, J. Dick, M. Lupien

The paper identifies transposable elements (TEs) as genetic drivers of stemness in normal and leukemic hematopoiesis, showing their role in maintaining stem cell properties through chromatin accessibility.

bioRxiv · Feb 16, 2021Cancer Biology